Resources Top 5: Latitude 66 stands out after selling non-core copper-gold interest
NSW state budget reveals housing plan and ‘potential’ planning for a new metro
Road safety tech ‘missing’ from Aussie cars
Health Check: Like bloodthirsty sharks, offshore acquirers are circling cheap biotech assets
Lunch Wrap: Miners, REITs lift ASX this morning; Qantas hit by cybercrooks
Top 10 at 11: ASX jumps on open as copper and battery metals rally
Biocurious: Dimerix could be riding big and beautiful kidney drug success earlier than expected
Billionaire winners and losers: Who made and lost money in the 2025 financial year?
China’s dominance of the gallium market is near total – but there’s opportunity for Western disruptors
‘Very positive for the gas industry’: Omega’s Trevor Brown on ADNOC’s Santos bid
Contributors
Our Resident Experts
Mining
China’s dominance of the gallium market is near total – but there’s opportunity for Western disruptors
Explorers Podcast: Albion sees gold value in Yandal West greenstone
Explorers Podcast: Norm Seckold on uncovering Uvre’s New Zealand gold projects
Resources Top 5: Sunrise Energy Metals fills scandium war chest after oversubscribed SPP
Resources Top 5: Institutional investors attracted to Koonenberry’s golden success
Featured in Mining
Tech
ASX Tech June Winners: Defence tech stocks dominate record-breaking month
The four AI tools everyday Aussies are using to clock off sooner
AI ‘havoc’ warning: expert calls for radical solution
Xero aims to crack US market by buying accounting platform Melio Payments
BlackRock calls defence tech the next theme to watch as NATO shifts into rearm mode
Featured in Tech
Health & Biotech
Biocurious: Dimerix could be riding big and beautiful kidney drug success earlier than expected
Health Check: And the EOFY biotech winner is … gasp … a pot stock
Dr Boreham’s Crucible: ‘Better not louder’, Audeara is tuned in to the global audiology market
Health Check: Tetratherix breaks biotech IPO drought with 13pc gain on debut
Health Check: Paradigm makes scenic acquisitive detour, but it’s no strategic shift
Featured in Health & Biotech
Experts
Why investors buy stocks at record prices
Criterion: Virgin’s trumphant float means more IPOs should be cleared for take-off
Stock Tips: Expert eyes are on WiseTech and Santos this week
The ‘outlandish’ property schemes hurting homebuyers
Is it time to move on from ‘old gold’ defensive strategies?
The four traits of successful investors
Broker Upgrades: WA gold developer becomes Canaccord’s latest ‘spec buy’
